March 30, 2017Open Access

Economic evaluation of medicines

Key Points

Key points are not available for this paper at this time.

Abstract

In Australia the government must balance access to new drugs against the cost to the Pharmaceutical Benefits Scheme. Economic evaluations can be used to ensure health resources are allocated efficiently, maximising patient outcomes for every dollar spent.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Taylor et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69dbc3c03d9adb00e7684f12 — DOI: https://doi.org/10.18773/austprescr.2017.014

Authors

Colman Taylor

Stephen Jan

Journals

Australian Prescriber

Actions

Institutions

The University of Sydney

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Cost-Effectiveness Analysis and the Consistency of Decision Making· 2001 · 437 citations
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE· 1958 · 258 citations
QUALMS ABOUT QALYs· 1987 · 95 citations
Willingness to pay for antihypertensive therapy — further results· 1993 · 126 citations
Pharmacoeconomic Guidelines: Where Do We Go from Here?· 2001 · 3 citations

Economic evaluation of medicines

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Also consider